Oncogene buys back 1.25 million shares
This article was originally published in Clinica
Executive Summary
Oncogene Science has bought back 1.25 million shares from Becton Dickinson for $8.75 million. In December 1996, Oncogene formed a collaboration with Bayer to provide funding to continue R&D for Oncogene's serum-based products for use in diagnostic oncology.